You are using an older browser version. Please use a supported version for the best MSN experience.

Fda Panel Endorses Booster Shot For J&J COVID-19 Vaccine

U.S. health advisers on Friday tackled who should get boosters of Johnson & Johnson's single-shot COVID-19 vaccine and when and whether using a competing brand for the second dose might provide better protection.The push for boosters kicked off last month after the Food and Drug Administration authorized third doses of the Pfizer vaccine for seniors and younger adults with health problems, jobs or living conditions that place them at higher risk from the coronavirus. On Thursday, an FDA advisory panel unanimously recommended a half-dose booster of the similar Moderna vaccine for the same groups.SEE MORE: FDA Panel Endorses Moderna COVID Vaccine Booster ShotFriday, the same panel discussed a booster of J&J's vaccine but the decision is more complex. Moderna and Pfizer asked the FDA to OK boosters at least six months after immunization, but J&J proposed a sliding schedule with an extra dose as early as two months later.Adding another twist, the experts also will discuss preliminary data from a government "mix-and-match" study that suggested J&J recipients may have a far stronger immune response if they get either a Moderna or Pfizer booster rather than a second J&J dose.The FDA will use its advisers' recommendations to decide whether to authorize boosters for both J&J and Moderna, likely next week, after which another government agency will rule on who should roll up their sleeves.All three vaccines in the U.S. still offer strong protection against severe illness and death from COVID-19 and the nation's priority remains getting first doses to 66 million eligible but unvaccinated Americans who are most at risk as the extra-contagious Delta variant continues to circulate.
image beaconimage beaconimage beacon